NYSE MKT
AMPE

Ampio Pharm

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Ampio Pharm Stock Price

Vitals

Today's Low:
$0.22
Today's High:
$0.25
Open Price:
$0.22
52W Low:
$0.199
52W High:
$9.705
Prev. Close:
$0.23
Volume:
34700

Company Statistics

Market Cap.:
$4.20 million
Book Value:
0.918
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-81.42%
Return on Equity TTM:
-130.71%

Company Profile

Ampio Pharm had its IPO on 2010-03-31 under the ticker symbol AMPE.

The company operates in the Healthcare sector and Biotechnology industry. Ampio Pharm has a staff strength of 9 employees.

Stock update

Shares of Ampio Pharm opened at $0.22 at the start of the last trading session i.e. 2023-03-25.

The stocks traded within a range of $0.22 - $0.25, and closed at $0.25.

This is a +8.7% increase from the previous day's closing price.

A total volume of 34,700 shares were traded at the close of the day’s session.

In the last one week, shares of Ampio Pharm have slipped by -16.67%.

Ampio Pharm's Key Ratios

Ampio Pharm has a market cap of $4.20 million, indicating a price to book ratio of 0.2989 and a price to sales ratio of 0.

In the last 12-months Ampio Pharm’s revenue was $0 with a gross profit of $0 and an EBITDA of $-25781000. The EBITDA ratio measures Ampio Pharm's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ampio Pharm’s operating margin was 0% while its return on assets stood at -81.42% with a return of equity of -130.71%.

In Q3, Ampio Pharm’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Ampio Pharm’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-2.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ampio Pharm’s profitability.

Ampio Pharm stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.4699. Its price to sales ratio in the trailing 12-months stood at 0.

Ampio Pharm stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$18.84 million
Total Liabilities
$3.92 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Ampio Pharm ended 2023 with $18.84 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.84 million while shareholder equity stood at $13.85 million.

Ampio Pharm ended 2023 with $0 in deferred long-term liabilities, $3.92 million in other current liabilities, 2000.00 in common stock, $-231719000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $16.95 million and cash and short-term investments were $16.95 million. The company’s total short-term debt was $332,000 while long-term debt stood at $0.

Ampio Pharm’s total current assets stands at $18.32 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $218000.00 and inventory worth $0.00.

In 2023, Ampio Pharm's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Ampio Pharm paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
$0.25
52-Week High
$9.705
52-Week Low
$0.199
Analyst Target Price
$4

Ampio Pharm stock is currently trading at $0.25 per share. It touched a 52-week high of $9.705 and a 52-week low of $9.705. Analysts tracking the stock have a 12-month average target price of $4.

Its 50-day moving average was $0.28 and 200-day moving average was $0.99 The short ratio stood at 1.37 indicating a short percent outstanding of 0%.

Around 750.6% of the company’s stock are held by insiders while 281.7% are held by institutions.

Frequently Asked Questions About Ampio Pharm

The stock symbol (also called stock or share ticker) of Ampio Pharm is AMPE

The IPO of Ampio Pharm took place on 2010-03-31

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$19.26
-0.7
-3.51%
$20.35
0.23
+1.14%
$24.29
0.61
+2.58%
$42.56
0.09
+0.21%
Immunic Inc (IMUX)
$1.48
-0.01
-0.67%
$2.7
0.03
+1.12%
$0.05
-0
-1.95%
Ggtoor Inc (GTOR)
$0.01
0
0%
$0.04
-0
-2.22%

Most Active

Last Price
Chg
Chg%
$0
0
0%
$0.11
0
0%
$0
0
+28.57%
$1.72
0.59
+52.21%
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+58723.53%
$0
0
+20460.42%
$0.63
0
+2548.22%
$0.02
0
+1566.67%

Top Losers

Last Price
Chg
Chg%
$0
-0.09
-99.33%
NGC-WT (NGC-WT)
$0
-0.04
-94.66%
$4.7
-33.3
-87.63%
Imara Inc (IMRA)
$21
0
-78.71%

About

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Address

373 Inverness Parkway, Englewood, CO, United States, 80112